Ready-CEPT Cell Viability Enhancer (Chroman-1, Emricasan, Polyamines, and trans-ISRIB)

Ready-CEPT Cell Viability Enhancer (Chroman-1, Emricasan, Polyamines, and trans-ISRIB)

Catalog Number:
MAR1518066DEF
Mfr. No.:
LSS-301-10-12/200-1/200-12
Price:
$360
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Ready-CEPT is a single-vial cocktail of chroman-1 (a ROCK inhibitor), emricasan (a pan-caspase inhibitor), polyamines (putrescine, spermine, and spermidine; polycations for cell growth support), and trans-ISRIB (an ISR inhibitor). CEPT was originally developed at the National Institutes of Health (NIH), where it was found to improve single-cell cloning and sorting, as well as improved viability and cell health. These benefits were well-characterized in particular for genetically stable stem cell culture, with benefits in cell passaging, cryoprotection, organoid and embryoid body (EB) formation, and gene editing, with fewer apparent off-target effects compared to other similar products on the market (e.g. Y-27632).

          Ready-CEPT is provided as a 1000X cocktail in a DMSO/water mixture, all using animal origin-free componentry.

          Ready-CEPT 1000X is provided in liquid form in 10- and 200-µL volumes, sufficient for 10 and 200 mL of CEPT-supplemented medium, respectively. This supplement can be used with a wide range of formulations, including the fully defined HiDef-B8 medium.

          Each lot of Ready-CEPT is used in combination with HiDef-B8 medium in performance testing in a culture assay evaluating using human iPSCs.

          Please contact us at for specific academic pricing.

      • Properties
        • * For research use only.

      • Applications
        • Application Description
          Ready-CEPT 1000X cocktail is a defined formulation designed for improved stem cell survival and growth during routine passaging, cryopreservation, and freeze-thaw recovery.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.